Agios Pharmaceuticals (AGIO)
(Real Time Quote from BATS)
$47.41 USD
+1.87 (4.11%)
Updated Sep 19, 2024 03:18 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Agios Pharmaceuticals, Inc. [AGIO]
Reports for Purchase
Showing records 101 - 120 ( 310 total )
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Model Revisions Post-4Q21 Results; Reiterate Buy and $96 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 18
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
FY2021 Results; Post-Approval Pyrukynd Revenues by 1Q22; Reiterate Buy and Decrease PT to $96 from $98
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Announces Pyrukynd?s Annual Price to Treat Patients with PKD; Reiterate Buy and $98 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Fully Rebooted Post-FDA Pyrukynd Approval in PKD; Reiterate Buy and Raise PT to $98 from $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 21.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended January 14.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Agios Previews Milestones and Strategy for 2022; Reiterate Buy and $95 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended December 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended December 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: Research Department
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended December 10
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Two Studies at ASH Corroborate Previous Findings for Mitapivat; Reiterate Buy and $95 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Agios Pharmaceuticals, Inc.
Industry: Medical - Products
Weekly Retail Sales Tracker for Hem. Malignancies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D